Phase 2 N=22 Treatment

Sildenafil for Treatment of Choroidal Ischemia

Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration · Central Serous Retinopathy · Retinitis Pigmentosa

Bottom Line

View on ClinicalTrials.gov: NCT04356716 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2025

Primary outcome: Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Sildenafil (Drug); Standard of Care Sildenafil (Other); Ocular Coherence Tomography-Angiography (OCT-A) (Diagnostic_test); Visual Acuity (VA) (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Columbia University
Primary completion: Feb 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Visual Acuity (Sildenafil Group)	0.00; -0.03	—
PRIMARY Change in Visual Acuity (Medical Record Review Group)	0.00; 0.00	—

Summary

The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.

Eligibility Criteria

Inclusion Criteria

Diagnosis of retinal and choroidal degenerations (reticular or vitelliform AMD or vitelliform-type subretinal drusen) or hereditary or acquired retinal dystrophies (retinitis pigmentosa or central serous retinopathy)

Exclusion Criteria

Diagnosis of heart disease requiring use of nitrates
Inability to be examined monthly or bi-monthly

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04356716). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.